Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: results of a controlled study of etilefrine versus placebo

Servei de Cardiologia, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.

OBJECTIVES. This study assessed the efficacy of oral etilefrine (10 mg three times a day) in preventing a positive response to head-up tilt testing. BACKGROUND. Previous reports have suggested that oral etilefrine can be effective either in preventing a positive response to head-up tilt testing or in reducing syncopal recurrences in patients with vasovagal syncope. Up to now most studies assessing drug therapy in these patients have been uncontrolled. METHODS. This was a randomized double-blind crossover study of etilefrine versus placebo in 30 consecutive patients with syncope and a baseline positive head-up tilt test. After the first test, patients had no treatment for 3 days and were randomized to receive etilefrine or placebo for 4 additional days. They underwent tilt testing under treatment and again after 3 days of washout; they then received the alternative treatment for 4 days, and a third test was performed. RESULTS. Head-up tilt test results were negative in 13 (43%) patients with etilefrine and 15 (50%) with placebo (p = NS). Therefore, the statistical power of the study was only 10%. The rate of positive responses decreased with repeated testing irrespective of the assigned treatment: A positive response was obtained during the second head-up tilt test in 20 patients (10 with placebo, 10 with etilefrine) but in only 12 during the third (7 with etilefrine, 5 with placebo) (p < 0.05). CONCLUSIONS. Oral etilefrine (10 mg three times a day) was not superior to placebo in preventing a positive response to head-up tilt testing. Despite a low statistical power, the high rate of negative response with placebo (50%) suggests that controlled trials are needed to assess the real efficacy of any treatment in patients with vasovagal syncope.

This article has been cited by other articles:

				M. P. Tan and S. W. Parry Reply. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2372 - 2373. [Full Text] [PDF]

				S. Petkar and A. Fitzpatrick Tilt-table testing: transient loss of consciousness discriminator or epiphenomenon? Europace, June 1, 2008; 10(6): 747 - 750. [Full Text] [PDF]

				M. Brignole, F. Giada, A. Raviele, and J. J. Blanc Pacing for syncope: what role? which perspective? Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I37 - I43. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association Europace, October 1, 2007; 9(10): 959 - 998. [Full Text] [PDF]

				Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association Eur. Heart J., September 2, 2007; 28(18): 2256 - 2295. [Full Text] [PDF]

				G. N. Theodorakis, D. Leftheriotis, E. G. Livanis, P. Flevari, G. Karabela, N. Aggelopoulou, and D. Th. Kremastinos Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Europace, March 1, 2006; 8(3): 193 - 198. [Abstract] [Full Text] [PDF]

				Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology Europace, January 1, 2004; 6(6): 467 - 537. [Full Text] [PDF]

				J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, and J. Soler-Soler Reproducibility of sequential head-up tilt testing in patients with recent syncope, normal ECG and no structural heart disease Eur. Heart J., November 1, 2002; 23(21): 1706 - 1713. [Abstract] [Full Text] [PDF]

				P. Flevari, E. G. Livanis, G. N. Theodorakis, E. Zarvalis, T. Mesiskli, and D. T. h Kremastinos Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being J. Am. Coll. Cardiol., August 7, 2002; 40(3): 499 - 504. [Abstract] [Full Text] [PDF]

				C. Kouakam, G. Vaksmann, E. Pachy, D. Lacroix, C. Rey, and S. Kacet Long-term follow-up of children and adolescents with syncope; predictor of syncope recurrence Eur. Heart J., September 1, 2001; 22(17): 1618 - 1625. [Abstract] [PDF]

				Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al. Guidelines on management (diagnosis and treatment) of syncope Eur. Heart J., August 1, 2001; 22(15): 1256 - 1306. [Abstract] [PDF]

				A. H. Madrid, J. Ortega, J. G. Rebollo, J. G. Manzano, J. G. Segovia, A. Sanchez, G. Pena, and C. Moro Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study J. Am. Coll. Cardiol., February 1, 2001; 37(2): 554 - 559. [Abstract] [Full Text] [PDF]

				R. Sheldon and S. Rose Components of clinical trials for vasovagal syncope Europace, January 1, 2001; 3(3): 233 - 240. [Abstract] [PDF]

				A. Raviele, F. Giada, R. Sutton, P. Alboni, M. Brignole, A. Del Rosso, E. di Girolamo, R. Luise, and C. Menozzi The Vasovagal Syncope and Pacing (Synpace) trial: rationale and study design Europace, January 1, 2001; 3(4): 336 - 341. [Abstract] [PDF]

				S.W. Parry and R.A. Kenny The management of vasovagal syncope QJM, December 1, 1999; 92(12): 697 - 705. [Full Text] [PDF]

				D. G. Benditt, G. J. Fahy, K. G. Lurie, S. Sakaguchi, W. Fabian, and N. Samniah Pharmacotherapy of Neurally Mediated Syncope Circulation, September 14, 1999; 100(11): 1242 - 1248. [Abstract] [Full Text] [PDF]

				A. Raviele, M. Brignole, R. Sutton, P. Alboni, P. Giani, C. Menozzi, and A. Moya Effect of Etilefrine in Preventing Syncopal Recurrence in Patients With Vasovagal Syncope : A Double-Blind, Randomized, Placebo-Controlled Trial Circulation, March 23, 1999; 99(11): 1452 - 1457. [Abstract] [Full Text] [PDF]

				J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, T. Rius-Gelabert, L. Mont Girbau, and J. Soler-Soler Clinical usefulness of head-up tilt test in patients with syncope and intraventricular conduction defect Europace, January 1, 1999; 1(1): 63 - 68. [Abstract] [PDF]

				D. Flammang, M. Antiel, T. Church, A. Chassing, D. Hamani, E. Donal, and M. Waynberger Is a pacemaker indicated for vasovagal patients with severe cardioinhibitory reflex as identified by the ATP test?: A preliminary randomized trial Europace, January 1, 1999; 1(2): 140 - 145. [Abstract] [PDF]

				C R Ward, J C Gray, J J Gilroy, and R A Kenny Midodrine: a role in the management of neurocardiogenic syncope Heart, January 1, 1998; 79(1): 45 - 49. [Abstract] [Full Text] [PDF]